Alumis

Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases designed to improve health outcomes – empowering people to reimagine their lives. What sets us apart is our precision approach to R&D. Our proprietary data analytics platform integrates genetic, genomic, proteomic, biological, and clinical insights to pinpoint the right targets, molecules, indications, patients, endpoints, and combinations – potentially accelerating development, enhancing therapy precision, and improving the probability of clinical success. Combined with our integrated approach to drug development, we believe this will drive smarter, faster progress against immune dysfunction.